Pharmacological modulation of Th17.
Recently, a third subset of Th17 cells has been described. This T helper subset induces the release of chemokines and growth factors and causes neutrophil accumulation in several mammalian organs. Pharmacological intervention blocking Th17 generation as well as IL-17 signaling might prove useful in a variety of diseases including asthma, chronic obstructive pulmonary disease, Crohn's disease, cystic fibrosis, multiple sclerosis, psoriatic disease and rheumatoid arthritis. Here, we describe the patents that address a potential pharmacological use of promoting or targeting IL-17.
De Sanctis
Juan B
JB
Institute of Immunology, Faculty of Medicine, Apartado Postal 50109, Caracas, Venezuela. sanctisj@gmail.com
Garmendia
Jenny V
JV
Moreno
Dolores
D
Larocca
Nancy
N
Mijares
Michael
M
Di Giulio
Camilo
C
Salazar-Bookaman
Margarita
M
Wojewodka
Gabriella
G
Radzioch
Danuta
D
D000818:Animals; D018926:Anti-Allergic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy* / Q000276:immunology; D020381:Interleukin-17 / Q000037:antagonists & inhibitors* / Q000276:immunology; D015398:Signal Transduction / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer / Q000187:drug effects* / Q000276:immunology
D018926:Anti-Allergic Agents; D016207:Cytokines; D020381:Interleukin-17